Lupin Limited has announced the commercial launch of Dapagliflozin Tablets in the United States market, marking another significant milestone in the company's diabetes care portfolio expansion. The launch follows the approval of the company's Abbreviated New Drug Application from the US FDA, demonstrating Lupin's continued success in navigating complex regulatory processes for diabetes medications.

Product Launch Details

The pharmaceutical company has commenced the launch of Dapagliflozin Tablets in two key dosage strengths in the American market. The FDA has approved Lupin's formulation as bioequivalent to Farxiga® for the indications specified in the approved labeling, ensuring therapeutic equivalence for healthcare providers and patients.

Strategic Market Expansion

This launch represents Lupin's continued commitment to expanding its presence in the US diabetes treatment market. The addition of Dapagliflozin Tablets complements the company's existing diabetes care portfolio and provides healthcare professionals with additional treatment options for their patients. The successful launch demonstrates Lupin's capability to bring complex pharmaceutical products to market efficiently.

Company Profile and Global Presence

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with an extensive distribution network spanning over 100 markets worldwide. The company maintains a diversified portfolio encompassing branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing facilities and 7 research centers globally, Lupin employs over 24,000 professionals dedicated to improving patient health outcomes across multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

Lupin Limited has announced the grant of 6,495 stock options to its employees under the company's established employee stock option plan. The grant was approved by the Nomination and Remuneration Committee on April 09, 2026, and disclosed to stock exchanges in compliance with regulatory requirements.

Stock Option Grant Details

The pharmaceutical company granted the options under its existing Lupin Employees Stock Option Plan 2011. All 6,495 options were allocated under this single plan structure.

Vesting and Exercise Terms

Each stock option entitles the grantee to subscribe to one equity share of the company valued at ₹2.00 upon successful vesting. The company has structured the vesting schedule to promote employee retention and long-term commitment.

The vesting schedule follows a systematic approach:

• 25% of options vest after completion of one year from grant date
• 25% vest after completion of two years
• 25% vest after completion of three years
• 25% vest after completion of four years

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was communicated to both the National Stock Exchange of India Limited and BSE Limited through official channels.

The grant represents part of Lupin's ongoing employee incentive strategy, designed to align employee interests with shareholder value creation through equity participation in the company's growth.